Cargando…

Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis

PURPOSE: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We us...

Descripción completa

Detalles Bibliográficos
Autores principales: Gertz, Morie, Abonour, Rafat, Gibbs, Sarah N, Finkel, Muriel, Landau, Heather, Lentzsch, Suzanne, Lin, Grace, Mahindra, Anuj, Quock, Tiffany, Rosenbaum, Cara, Rosenzweig, Michael, Sidana, Surbhi, Tuchman, Sascha A, Witteles, Ronald, Yermilov, Irina, Broder, Michael S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503521/
https://www.ncbi.nlm.nih.gov/pubmed/37719133
http://dx.doi.org/10.2147/CEOR.S412079
_version_ 1785106538877157376
author Gertz, Morie
Abonour, Rafat
Gibbs, Sarah N
Finkel, Muriel
Landau, Heather
Lentzsch, Suzanne
Lin, Grace
Mahindra, Anuj
Quock, Tiffany
Rosenbaum, Cara
Rosenzweig, Michael
Sidana, Surbhi
Tuchman, Sascha A
Witteles, Ronald
Yermilov, Irina
Broder, Michael S
author_facet Gertz, Morie
Abonour, Rafat
Gibbs, Sarah N
Finkel, Muriel
Landau, Heather
Lentzsch, Suzanne
Lin, Grace
Mahindra, Anuj
Quock, Tiffany
Rosenbaum, Cara
Rosenzweig, Michael
Sidana, Surbhi
Tuchman, Sascha A
Witteles, Ronald
Yermilov, Irina
Broder, Michael S
author_sort Gertz, Morie
collection PubMed
description PURPOSE: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients. PATIENTS AND METHODS: Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time. RESULTS: During 1L therapy, 55% of advanced patients had ≥1 hospitalization and 38% had ≥2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥1 hospitalization: 20-43%, ≥2 hospitalizations: 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement. CONCLUSION: Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization.
format Online
Article
Text
id pubmed-10503521
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105035212023-09-16 Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis Gertz, Morie Abonour, Rafat Gibbs, Sarah N Finkel, Muriel Landau, Heather Lentzsch, Suzanne Lin, Grace Mahindra, Anuj Quock, Tiffany Rosenbaum, Cara Rosenzweig, Michael Sidana, Surbhi Tuchman, Sascha A Witteles, Ronald Yermilov, Irina Broder, Michael S Clinicoecon Outcomes Res Short Report PURPOSE: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients. PATIENTS AND METHODS: Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time. RESULTS: During 1L therapy, 55% of advanced patients had ≥1 hospitalization and 38% had ≥2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥1 hospitalization: 20-43%, ≥2 hospitalizations: 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement. CONCLUSION: Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization. Dove 2023-09-11 /pmc/articles/PMC10503521/ /pubmed/37719133 http://dx.doi.org/10.2147/CEOR.S412079 Text en © 2023 Gertz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Gertz, Morie
Abonour, Rafat
Gibbs, Sarah N
Finkel, Muriel
Landau, Heather
Lentzsch, Suzanne
Lin, Grace
Mahindra, Anuj
Quock, Tiffany
Rosenbaum, Cara
Rosenzweig, Michael
Sidana, Surbhi
Tuchman, Sascha A
Witteles, Ronald
Yermilov, Irina
Broder, Michael S
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
title Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
title_full Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
title_fullStr Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
title_full_unstemmed Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
title_short Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
title_sort using a modified delphi panel to estimate health service utilization for patients with advanced and non-advanced systemic light chain amyloidosis
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503521/
https://www.ncbi.nlm.nih.gov/pubmed/37719133
http://dx.doi.org/10.2147/CEOR.S412079
work_keys_str_mv AT gertzmorie usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT abonourrafat usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT gibbssarahn usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT finkelmuriel usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT landauheather usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT lentzschsuzanne usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT lingrace usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT mahindraanuj usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT quocktiffany usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT rosenbaumcara usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT rosenzweigmichael usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT sidanasurbhi usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT tuchmansaschaa usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT wittelesronald usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT yermilovirina usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis
AT brodermichaels usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis